Ian T. Lowitt, Chief Executive Officer and Director of Marex Group Ltd, filed a Form 4 on November 19, 2026, disclosing five open-market sales of ordinary shares totaling 16,232 shares on November 17, 2026, executed under a Rule 10b5-1 plan.
Key Highlights
- Reporting person: Ian T. Lowitt, CEO and Director of Marex Group Ltd (NASDAQ:MRX)
- Total shares sold: 16,232 ordinary shares disposed of on November 17, 2026, across five separate transactions
- Price range: Individual transaction weighted average prices ranged from $66.6369 to $70.39 per share, with underlying per-share sale prices spanning $66.14 to $70.39 across all tranches
- Remaining holdings: 2,819,240 ordinary shares beneficially owned directly following the reported transactions
- Deferred bonus shares: The post-transaction total includes 194,411 shares underlying deferred bonus plan awards previously granted, each representing a contingent right to receive one ordinary share upon vesting and settlement
- 10b5-1 plan: All sales were effected pursuant to a Rule 10b5-1 plan entered into by Lowitt on August 15, 2026
Lowitt's Five-Tranche Sale of Marex Ordinary Shares
According to the filing, Ian T. Lowitt sold ordinary shares of Marex Group Ltd in five separate tranches on November 17, 2026, all under a Rule 10b5-1 plan he entered into on August 15, 2026. The first tranche disposed of 4,962 shares at a weighted average price of $66.6369, with individual transactions ranging from $66.14 to $67.12. The second tranche covered 5,313 shares at a weighted average of $67.7135, with prices from $67.20 to $68.13.
The third tranche involved 4,004 shares at a weighted average of $68.5316, with prices ranging from $68.145 to $69.08. The fourth tranche disposed of 1,853 shares at a weighted average of $69.6809, with prices from $69.212 to $70.12. A fifth tranche of 100 shares was sold at $70.39. The filing notes that all weighted average prices are reported as such, and Lowitt "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."
Following all reported transactions, Lowitt directly held 2,819,240 ordinary shares, according to the filing. The filing discloses that this total includes 194,411 shares underlying deferred bonus plan awards previously granted to Lowitt, described as contingent rights to receive one ordinary share each upon vesting and settlement of the applicable award. The Form 4 was signed by Scott Linsley as Attorney-in-Fact for Ian T. Lowitt and filed on November 19, 2026.
What Was Disclosed
Marex Group Ltd CEO Ian T. Lowitt reported the sale of 16,232 ordinary shares on November 17, 2026, across five tranches under a pre-established Rule 10b5-1 plan, leaving him with direct beneficial ownership of 2,819,240 shares, including 194,411 contingent deferred bonus plan shares.



Please wait processing your request...